Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus

Background Patients with systemic lupus erythematosus (SLE) have a higher risk for cardiovascular disease (CVD), not fully explained by the conventional risk factors. These patients have endothelial dysfunction (ED) as an early process of atherosclerosis, which can be reversed with therapy. Objectiv...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2016-06, Vol.25 (7), p.741-748
Main Authors: Vera-Lastra, O, Méndez-Flores, S, Cruz-Dominguez, M P, Medina, G, Calderón-Aranda, E, Jara, L J
Format: Article
Language:English
Subjects:
Adult
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - adverse effects
Arteriosclerosis
Atherosclerosis
Atherosclerosis - prevention & control
Brachial Artery - diagnostic imaging
C-reactive protein
C-Reactive Protein - analysis
Cardiovascular diseases
Cholesterol
Cholesterol - blood
Drug Therapy, Combination
Endothelium, Vascular - drug effects
Endothelium, Vascular - physiopathology
Ezetimibe - administration & dosage
Ezetimibe - adverse effects
Female
High density lipoprotein
Humans
Low density lipoprotein
Lupus
Lupus Erythematosus, Systemic - complications
Male
Middle Aged
Pravastatin
Pravastatin - administration & dosage
Pravastatin - adverse effects
Risk factors
Systemic lupus erythematosus
Ultrasonography
Ultrasound
Vasodilation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patients with systemic lupus erythematosus (SLE) have a higher risk for cardiovascular disease (CVD), not fully explained by the conventional risk factors. These patients have endothelial dysfunction (ED) as an early process of atherosclerosis, which can be reversed with therapy. Objective To determine the effect of ezetimibe plus pravastatin on endothelial function in patients with SLE after 12 months of treatment. Patients and methods An open study, before and after, which assessed the effect of ezetimibe plus pravastatin treatment, was performed. Twenty two patients (21 women and one man) with diagnosis of SLE were studied, with a mean age 40 ± 5 years. Endothelial dysfunction was evaluated using vascular ultrasound of the brachial artery in order to measure the flow-mediated vasodilation (FMV) basal and after 12 months of treatment with pravastatin 40 mg/day plus ezetimibe 10 mg/day. In addition, a lipid profile: total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and serum C-reactive protein (CRP), was done. Results We found a basal FMV of 7.58% and 18.22% after 12 months of treatment, with an improvement of 10.64 points 95% CI (7.58–13.58), p 
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203316631631